Evidence map›Paper›PMID 35070044›Full record

ArticleWorld journal of gastrointestinal oncology2021

Dysbiosis of the duodenal microbiota as a diagnostic marker for pancreaticobiliary cancer.

Mitsuru Sugimoto, Kazumichi Abe, Tadayuki Takagi, Rei Suzuki, Naoki Konno, Hiroyuki Asama, Yuki Sato, Hiroki Irie, Ko Watanabe, Jun Nakamura and 7 more

Open access · diamondAbstract read
In one paragraph

Article in World journal of gastrointestinal oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.4field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 2 institutions in 1 country.

Mitsuru SugimotoDepartment of Gastroenterology, Fukushima Medical University School of Medicine, Fukushima 960-1295, Japan. kitachuuou335@yahoo.co.jp.
Kazumichi AbeDepartment of Gastroenterology, Fukushima Medical University School of Medicine, Fukushima 960-1295, Japan.
Tadayuki TakagiDepartment of Gastroenterology, Fukushima Medical University School of Medicine, Fukushima 960-1295, Japan.
Rei SuzukiDepartment of Gastroenterology, Fukushima Medical University School of Medicine, Fukushima 960-1295, Japan.
Naoki KonnoDepartment of Gastroenterology, Fukushima Medical University School of Medicine, Fukushima 960-1295, Japan.
Hiroyuki AsamaDepartment of Gastroenterology, Fukushima Medical University School of Medicine, Fukushima 960-1295, Japan.
Yuki SatoDepartment of Gastroenterology, Fukushima Medical University School of Medicine, Fukushima 960-1295, Japan.
Hiroki IrieDepartment of Gastroenterology, Fukushima Medical University School of Medicine, Fukushima 960-1295, Japan.
Ko WatanabeDepartment of Gastroenterology, Fukushima Medical University School of Medicine, Fukushima 960-1295, Japan.
Jun NakamuraDepartment of Gastroenterology, Fukushima Medical University School of Medicine, Fukushima 960-1295, Japan.
Hitomi KikuchiDepartment of Gastroenterology, Fukushima Medical University School of Medicine, Fukushima 960-1295, Japan.
Mika TakasumiDepartment of Gastroenterology, Fukushima Medical University School of Medicine, Fukushima 960-1295, Japan.
Minami HashimotoDepartment of Gastroenterology, Fukushima Medical University School of Medicine, Fukushima 960-1295, Japan.
Tsunetaka KatoDepartment of Gastroenterology, Fukushima Medical University School of Medicine, Fukushima 960-1295, Japan.
Ryoichiro KobashiDepartment of Gastroenterology, Fukushima Medical University School of Medicine, Fukushima 960-1295, Japan.
Takuto HikichiDepartment of Endoscopy, Fukushima Medical University Hospital, Fukushima 960-1295, Japan.
Hiromasa OhiraDepartment of Gastroenterology, Fukushima Medical University School of Medicine, Fukushima 960-1295, Japan.
Fukushima Medical University · JPFukushima Medical University Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPancreaticobiliary cancer (PB Ca) is a lethal disease, and a useful diagnostic marker is urgently needed. A correlation between the human microbiota and malignant gastrointestinal diseases was recently reported.

aimTo investigate the efficacy of the duodenal microbiota for diagnosing PB Ca.

methodsWe recruited 22 patients with benign pancreaticobiliary diseases (benign group) and 12 patients with PB Ca (malignant group). The duodenal microbiota of each patient was analyzed by the 16S rDNA terminal restriction fragment length polymorphism method. Patient characteristics, tumor markers, and relative abundances of the duodenal microbiota were compared between the benign and malignant groups.

resultsCancer antigen 19-9 (CA19-9),

conclusionThe duodenal microbiota may be useful for PB Ca screening.

Indexed as

Cancer antigen 19-9Clostridium cluster XVIIIDiagnostic markerDuodenal microbiotaPancreaticobiliary cancer

Identifiers

PMID35070044
PMCPMC8713320
OpenAlexW4200153486

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.